Strategic Funding Epic Sciences has recently closed a Series G funding round totaling around $24 million with co-leads Deerfield Management and Arsenal Capital Partners, signaling strong investor confidence and potential for expanded commercial and R&D collaborations in oncology diagnostics.

Clinical Partnerships The company already partners with leading pharmaceutical companies and major cancer centers globally, presenting ongoing opportunities to expand co-development, validation studies, and real-world evidence generation for liquid biopsy diagnostics and companion diagnostics.

Growth via DefineMBC launches DefineMBC a liquid biopsy test for metastatic breast cancer, indicating a strategic product line expansion that can open sales conversations with oncology practices, labs, and payers seeking non-invasive diagnostic solutions.

Headroom in CTC Tech Epic’s platform for rare cell analysis and circulating tumor cells positions it to upsell advanced monitoring, treatment customization, and resistance tracking solutions to biopharma partners and clinical labs investing in precision oncology.

Compliance and Cloud With a tech stack including cloud services and data platforms (Google Cloud, New Relic, Snowplow) and privacy tools (Osano), there is an opening to offer managed data integration, analytics, and compliance services to customers migrating to or expanding digital pathology and remote diagnostics.